SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Q3 Trading Update

21 Oct 2021 07:00

RNS Number : 7297P
Rentokil Initial PLC
21 October 2021
 

  

 

21 October 2021

RENTOKIL INITIAL PLC (RTO) - THIRD QUARTER TRADING UPDATE

Strong momentum across our core businesses in Q3, continued good execution of M&A

 

 

(£m)

Q3 2021

Growth

AER

AER

CER

Ongoing Revenue1

761.3

0.9%

4.8%

Revenue

761.9

0.5%

4.4%

Excluding Disinfection

Ongoing Revenue1

750.2

10.2%

14.5%

Revenue

750.8

9.7%

14.0%

 

Overview of Q3 performance (at CER)

Q3 saw continued strong momentum in our core businesses with Group Ongoing Revenue, excluding disinfection services, growing by 14.5%, of which 6.7% was Organic2 and 7.8% was from acquisitions.

Pest Control delivered an excellent performance overall during the period. Despite our Australian, New Zealand, Malaysian and Indonesian operations being materially impacted by lockdowns in Q3, the category grew Ongoing Revenues by 18.3%, of which 7.5% was Organic. Ongoing Revenue in our Growth and Emerging markets grew by 18.7% and 15.6% respectively. In our North America business, a higher number of colleagues either off work with COVID-19 or self-isolating contributed to some labour shortages in the quarter. Despite this, our Pest Control business in North America continued to demonstrate very strong momentum, growing revenues by 24.6%, 10.1% Organic.

Our Core Hygiene business, excluding disinfection, delivered a 6.4% increase in Ongoing Revenue (4.7% Organic), reflecting good performances in the UK, Europe and Latin America but held back, as with Pest Control, by significant challenges associated with lockdowns and movement restrictions in Australia, New Zealand, Indonesia and Malaysia.

Sales from disinfection services have tapered in line with our expectations at £11.4m (Q1: £75.7m, Q2: £22.6m), a decline of £62.1m on this time last year. We are maintaining our guidance for disinfection revenues in H2 to be within the range of £10m to £20m.

Ongoing Revenue in our Protect & Enhance category grew by 6.2% (5.5% Organic), reflecting further recovery in our France Workwear, Ambius, UK Property Care and Dental Hygiene services businesses.

New category structure - Hygiene & Wellbeing

At our Capital Markets Day on 28 September, we announced that in response to the increasing importance of hygiene and wellbeing services, we are expanding our Hygiene category with effect from 1 January 2022. The enlarged category, called Hygiene & Wellbeing, will comprise our current Hygiene operations together with our Ambius, Dental Hygiene and Cleanroom services operations, previously part of our Protect & Enhance category. Adopting the new category structure in Q3 would give organic growth in Hygiene & Wellbeing of 6.6%.

M&A

​We completed nine acquisitions in Q3: seven in Pest Control; one in Hygiene; and the previously announced transaction with Boecker, which completed on 3 August and which offers both Pest Control and Hygiene services. As a result, we have acquired businesses with operations in Australia, Chile, Colombia, Guadeloupe, Lebanon, Saudi Arabia, United Arab Emirates and the US, as well as interests in affiliated businesses in Kuwait, Qatar and Nigeria. Together, these have combined annualised revenues in the year prior to acquisition of c.£48m. Q2's excellent momentum has been maintained in Q3 and also into Q4, and our anticipated full year expenditure on M&A remains in the region of at least £450m to £500m, as previously guided.

Commenting on today's announcement Andy Ransom, Chief Executive, said:

"We have delivered a strong performance from our core businesses in the quarter and are confident of sustaining this momentum for the remainder of the year. Assuming no further significant deterioration in trading conditions arising from the pandemic, our performance in Q3 - combined with further progress in our value-creating M&A programme - means we remain on track to deliver a full year performance in line with the guidance given at our interim results in July."

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

Media:

Malcolm Padley

Rentokil Initial plc

07788 978199

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

 

AER - actual exchange rates; CER - constant 2020 exchange rates

 

This announcement contains statements that are, or may be, forward-looking regarding the Group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure Guidance and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPPGUAUUPGGQU
Date   Source Headline
17th Aug 201211:49 amRNSAmendment-Interim Results to 30.06.12
6th Aug 20125:20 pmRNSAcquisition
3rd Aug 20127:00 amRNSInterim Results for six months to 30.06.12
31st Jul 20123:52 pmRNSHolding(s) in Company
28th Jun 20129:23 amRNSDirector/PDMR Shareholding
9th May 20126:09 pmRNSAMENDING RNS released 16:51 - 09.05.12
9th May 20124:51 pmRNSDirector/PDMR Shareholding
8th May 20127:00 amRNSDirector/PDMR Shareholding
4th May 20127:00 amRNSInterim Management Statement - Q1
2nd May 20121:24 pmRNSResult of AGM
10th Apr 201210:39 amRNSPublication of Prospectus
29th Mar 20129:20 amRNSAnnual Financial Report
19th Mar 20123:58 pmRNSDirector/PDMR Shareholding
2nd Mar 201211:37 amRNSDividend - Record date amendment
2nd Mar 20127:00 amRNSFinal Results
24th Feb 20127:00 amRNSDirectorate Change
7th Feb 201211:48 amRNSHolding(s) in Company
3rd Feb 20124:37 pmRNSHolding(s) in Company
13th Jan 20129:41 amRNSHolding(s) in Company
6th Jan 20125:21 pmRNSHolding(s) in Company
21st Dec 20114:37 pmRNSHolding(s) in Company
5th Dec 20115:01 pmRNSAcquisition of MSS Facilities Management
30th Nov 20114:31 pmRNSHolding(s) in Company
28th Nov 20115:05 pmRNSHolding(s) in Company
21st Nov 20117:00 amRNSProposed acquisition of building services division
18th Nov 201112:49 pmRNSHolding(s) in Company
14th Nov 20119:32 amRNSHolding(s) in Company
11th Nov 20114:29 pmRNSHolding(s) in Company
7th Nov 20117:00 amRNSTrading update for 3rd quarter ended 30.09.11
17th Oct 20112:58 pmRNSHolding(s) in Company
12th Oct 20113:25 pmRNSHolding(s) in Company
5th Oct 20111:59 pmRNSHolding(s) in Company
5th Oct 201111:59 amRNSHolding(s) in Company
23rd Sep 20119:49 amRNSHolding(s) in Company
11th Aug 20118:30 amRNSDirector/PDMR Shareholding
10th Aug 20114:14 pmRNSHolding(s) in Company
3rd Aug 20111:58 pmRNSDirector/PDMR Shareholding
2nd Aug 20114:32 pmRNSHolding(s) in Company
29th Jul 20117:00 amRNSInterim results for six months to 30 June 2011
20th Jul 20117:00 amRNSMulti Country Contract with Rentokil
19th Jul 20114:11 pmRNSHolding(s) in Company
14th Jul 201112:54 pmRNSMerger Update
14th Jun 201111:00 amRNSMD and FD of City Link Appointed
13th Jun 20114:00 pmRNSMerger Update
12th May 20111:00 pmRNSResult of AGM
9th May 20111:29 pmRNSDirector/PDMR Shareholding
6th May 20117:00 amRNS1st Quarter Results
6th Apr 20114:00 pmRNSMerger Update
6th Apr 20117:00 amRNSCorporate Responsibility Report 2010
1st Apr 20115:30 pmRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.